Sugi Predict

Sugi Predict / Targets / PSMD2

PSMD2

26S proteasome non-ATPase regulatory subunit 2 · Q13200 · PSMD2 on Sugi Atlas →

6,166 patent compounds predicted against PSMD2, 4,719 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL3170187 SCHEMBL3170187 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL3170843 SCHEMBL3170843 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20

Clinical trials — most relevant to PSMD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone. nanUNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMD2 binder may also engage these)

ProteinNameSimilarity
Q5R9I6 — 1.000 Q5R9I6 →
Q8VDM4 — 1.000 Q8VDM4 →
P56701 — 1.000 P56701 →
Q4FZT9 — 1.000 Q4FZT9 →
Q9SIV2 — 1.000 Q9SIV2 →
Q6XJG8 — 0.999 Q6XJG8 →
Q9QZE5 — 0.991 Q9QZE5 →
P87048 — 0.991 P87048 →
Q7S8R8 — 0.990 Q7S8R8 →
COPG1 Coatomer subunit gamma-1 0.990 landscape →
P53620 — 0.990 P53620 →
Q9I8E6 — 0.989 Q9I8E6 →
Q9PUE4 — 0.989 Q9PUE4 →
Q9QXK3 — 0.989 Q9QXK3 →
Q54BC6 — 0.988 Q54BC6 →
Q9MAT0 — 0.987 Q9MAT0 →
Q66JI9 — 0.987 Q66JI9 →
Q0WW26 — 0.987 Q0WW26 →
COPG2 Coatomer subunit gamma-2 0.987 landscape →
Q0CNR3 — 0.987 Q0CNR3 →
NAT10 RNA cytidine acetyltransferase 0.986 landscape →
Q6DKD7 — 0.986 Q6DKD7 →
Q6FPV6 — 0.986 Q6FPV6 →
Q9V3P6 — 0.985 Q9V3P6 →
Q8I0G5 — 0.985 Q8I0G5 →
Q29AE5 — 0.985 Q29AE5 →
P22892 — 0.985 P22892 →
A2VE21 — 0.984 A2VE21 →
Q9C5Z3 — 0.983 Q9C5Z3 →
AP1G1 AP-1 complex subunit gamma-1 0.983 landscape →